26/11/2025
3 part series of Alzheimer’s disease
Anti-amyloid β monoclonal antibodies are reshaping the outlook for Alzheimer’s disease for the first time in over a century.
The Lancet three-part series covers updated diagnostic criteria, advances in biological treatments alongside traditional care, and key debates on disease concepts, health-care impact, and future solutions in diagnosis, treatment, and prevention.
🔗 https://bit.ly/4oXSNzR